Table 1. Using PBNA to detect the influence of SARS-CoV-2 variants of concern (VOCs) on the effectiveness of four vaccines.
| Vaccine | WHO EUL holder | Sample size | Days post second vaccine dose | Reference strain | B.1.1.7 | P.1 | B.1.351 | B.1.617.2 | B.1.1.529 | References |
|---|---|---|---|---|---|---|---|---|---|---|
| BNT162b2 | Pfizer/BioNTech | 32 | 19–32d | WT | NA | NA | 6.7-fold decreases | 2.2-fold decreases | 22.8-fold decreases | Muik et al. (2022) |
| 26 | 26d | D614G | 1.3-fold decreases | NA | 3.2-fold decreases | 2.2-fold decreases | 28.6-fold decreases | Evans et al. (2022) | ||
| 30 | 7–32d | WT | 2.1-fold decreases | 6.7-fold decreases | 34.5-fold decreases | NA | NA | Tang et al. (2022) | ||
| Ad26.COV2-S | Janssen | 20 | 30d | WT | NA | NA | 12.6-fold increases | 5.97-fold increases | 12.6-fold increases | Liu et al. (2022) |
| mRNA-1273 | Moderna | 7 | 14d | D614G | NA | NA | 8.9-fold decreases | NA | 35.1-fold decreases | Wu et al. (2021a) |
| 8 | 7d | D614G | 1.2-fold decreases | 3.2-fold decreases | 6.9-fold decreases | 2.7-fold decreases | NA | Barouch et al. (2021), p. 19 | ||
| CoronaVac | Sinovac | 20 | 14d | WT | 2.9-fold increases | 4.3-fold increases | 5.5-fold increases | 3.4-fold increases | 12.5-fold increases | Wang et al. (2022a) |
Note:
WT, wild type (Wuhan strain); D614G, virus Spike protein acquired the D614G mutation, early in the pandemic, replacing the Wuhan strain as a globally prevalent strain, but with no reduction in vaccine protective effect compared to the Wuhan strain (Weissman et al., 2020); NA, not available.